Clariscan, approved in more than 55 countries globally with over four million patient doses shipped, is now FDA-approved in the U.S. Expands the GE Healthcare portfolio of contrast media products “The ...
The US Food and Drug Administration (FDA) has granted expanded clearance to Bayer’s Medrad MRXperion, broadening the magnetic resonance (MR) injection system’s application across a wider range of MRI ...
VUEWAY ® (gadopiclenol) solution for injection, 485.1 mg/mL is a macrocyclic gadolinium-based contrast agent (GBCA) that offers effective contrast enhancement at half the gadolinium (Gd) dose (0.05 ...
BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an ...
We are looking for volunteers to undergo magnetic resonance imaging (MRI) scans of the brain, with gadolinium-based contrast agent injection. Participants will be paid $80. The total scan duration is ...
The launch of Pixxoscan expands GE HealthCare’s portfolio of Magnetic Resonance Imaging (MRI) contrast agents, now offering two leading macrocyclic molecules to customers - Clariscan (gadoteric acid) ...
Widespread neurological conditions, including Alzheimer’s disease, Parkinson’s disease, epilepsy, multiple sclerosis, stroke, and brain tumors, are among the top causes of disability and death around ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results